AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
AIM ImmunoTech Inc. will present at the MedInvest Biotech & Pharma Investor Conference on April 3rd, 2024. Thomas K. Equels, CEO, will discuss company updates and meet with investors.
03/28/2024 - 08:05 AM
Live webcast presentation on Wednesday, April 3rd at 1:35 PM ET
OCALA, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM ImmunoTech, will present at the MedInvest Biotech & Pharma Investor Conference being held in New York, N.Y., on Wednesday, April 3, 2024, at 1:35 PM ET.
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, please visit the conference website .
A live webcast of the presentation will be available on the Events page of Investors section of the Company’s website (www.aimimmuno.com ).
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook .
When is AIM ImmunoTech Inc. presenting at the MedInvest Biotech & Pharma Investor Conference?
AIM ImmunoTech Inc. will present on April 3rd, 2024, at 1:35 PM ET.
Who will be presenting at the conference from AIM ImmunoTech Inc.?
Thomas K. Equels, the CEO of AIM ImmunoTech Inc., will be presenting.
What is the purpose of the presentation at the conference?
The presentation will discuss company updates and meet with investors for one-on-one meetings.
Where is the MedInvest Biotech & Pharma Investor Conference being held?
The conference is being held in New York, N.Y.
How can investors participate in the one-on-one meetings with AIM ImmunoTech Inc. management?
Qualified members of the investor community registered for the conference can participate in the one-on-one meetings.
AIM Rankings
#3581 Ranked by Stock Gains
AIM Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Ocala
About AIM
aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as
